RADX Stock — Radiopharm Theranostics Limited: Cash, EV, Pipeline

What they do

We develop targeted and scientifically validated radiopharmaceutical technologies that are in both pre-clinical and clinical stages of development. These technologies span all size molecules comprising peptides, small molecules and antibodies attached to medical quality radioisotopes.

Source: 20-F FY2026 via SEC EDGAR

Share price

$0.76

Market cap

$11.0M

Cash

$29.1M

Enterprise value

-$18.1M

Balance sheet

Cash	$29.1M
Debt	$0.0M
Net cash	$29.1M
Enterprise value	-$18.1M
Basic shares	14.5M shares
Fully diluted shares	20.2M shares
Fully diluted market cap	$15.3M
Cash per share	$2.01
Quarterly burn	$9.2M
Cash runway	3.2 quarters

Cash figures as of 2025-06-30. Database snapshot: 2026-11-13.

Share structure

Common

11.8M

Pre-funded warrants

0.0M

Options

8.3M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

20.2M

Cap table components pending verification.

Price history

Loading RADX daily closes…

Loading price history…

Next catalyst

RAD 402 · Est. Nov 14, 2026 · half midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 14, 2026 Now half midpoint	RAD 402 Phase 1 in advanced prostate cancer · NCT07259213	Phase 1	advanced prostate cancer	2H 2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

177Lu-BetaBart

Stage not disclosed · Active Modality: radioantibody (177Lutetium-conjugated anti-B7-H3)

Target B7-H3

Partnerships AtomVie Global Radiopharma (development and manufacturing services)

Status note 177Lutetium-conjugated B7-H3 radioantibody. Phase and indication not disclosed in the filing; other licensed programs in the 20-F do not name distinct candidates with stages and indications.

Per-asset detail extracted from the 20-F filed 2025-09-18. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Stonepine Capital	51,000,000	no change	0.51%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

RADX — Radiopharm Theranostics Limited ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Specialist fund holders

Latest news

RADX — Radiopharm Theranostics Limited